Characterization shows MSK adverse events are common after hormonal treatment for breast cancer. **Join the journey to PLE**

**INTRO**
Large RCTs have shown that Aromatase Inhibitors improve breast cancer survival, but have also suggested increased incidence of MSK side effects compared to traditional Tamoxifen. This study aimed to characterize women and adverse events associated with estrogen blockade after breast cancer, to determine if it is feasible to move to PLE study within the OHDSI Network.

**METHODS**
1. Women aged >55y with known breast cancer & new use of Aromatase Inhibitor vs Tamoxifen
2. ATLAS was used with IQVIA, CPRD & SIDIAP data to determine if possible to take study to collaborators
3. Outcomes:
   - Carpal tunnel syndrome
   - Osteoarthritis (shoulder, hand & wrist, hip, knee)
   - Tendinopathy (shoulder, elbow, hand & wrist, hip, knee)

**RESULTS**